Sponsor: Clovis Oncology, Inc.
Protocol CO-338-100. A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated with Deleterious Mutations in Homologous Recombination Repair Genes.
Single agent PARP inhibitor rucaparib for patients with a solid tumor that has a mutation in any of the following genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B.
For more information please contact the clinical research department: 631-675-5075